 Kazia Therapeutics Ltd ASX:KZA NASDAQ:KZIA FRA:NV9M directors have demonstrated their confidence in the companys biotech strategy with on-market purchases. Non-executive director Steven Coffey acquired 7,250 shares at 1.40 per share in an indirect interest between April 30 and May 3, increasing the number of securities held in that interest to 418,250 shares with another 8,015 held in a direct interest. 